[HTML][HTML] Molecular stress-inducing compounds increase osteoclast formation in a heat shock factor 1 protein-dependent manner
RC Chai, MM Kouspou, BJ Lang, CH Nguyen… - Journal of Biological …, 2014 - ASBMB
Many anticancer therapeutic agents cause bone loss, which increases the risk of fractures
that severely reduce quality of life. Thus, in drug development, it is critical to identify and
understand such effects. Anticancer therapeutic and HSP90 inhibitor 17-(allylamino)-17-
demethoxygeldanamycin (17-AAG) causes bone loss by increasing osteoclast formation, but
the mechanism underlying this is not understood. 17-AAG activates heat shock factor 1
(Hsf1), the master transcriptional regulator of heat shock/cell stress responses, which may …
that severely reduce quality of life. Thus, in drug development, it is critical to identify and
understand such effects. Anticancer therapeutic and HSP90 inhibitor 17-(allylamino)-17-
demethoxygeldanamycin (17-AAG) causes bone loss by increasing osteoclast formation, but
the mechanism underlying this is not understood. 17-AAG activates heat shock factor 1
(Hsf1), the master transcriptional regulator of heat shock/cell stress responses, which may …
